Contra-indicated in patients with active pathological bleeding.
- TRADE NAME: Plavix (Bristol-Myers Squibb, Sanofi-Aventis)
- INDICATIONS: Acute coronary syndrome, recent myocardial infarction, recent stroke, or established peripheral arterial disease
- CLASS: Antiplatelet (antithrombotic), Antiplatelet; thienopyridine
- HALF-LIFE: 6 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amiodarone, Anisindione, Anticoagulants, Atorvastatin, Calcium channel blockers, Cangrelor, Carbamazepine, Chloramphenicol, Cimetidine, Ciprofloxacin, Collagenase, Dabigatran, Dasatinib, Delavirdine, Dexlansoprazole, Diclofenac, Dicumarol, Dipyridamole, Drotrecogin Alfa, Efavirenz, Enoxaparin, Erythromycin, Esomeprazole, Etravirine, Fluconazole, Fluoxetine, Fluvoxamine, Fondaparinux, Glucosamine, Herbals with anticoagulant properties, Ibritumomab, Iloprost, Inotersen, Itraconazole, Ketoconazole, Lansoprazole, Lepirudin, Macrolide antibiotics, Meloxicam, Miconazole, Moclobemide, NSAIDs, Omega-3 Fatty Acids, Omeprazole, Oxcarbazepine, Pantoprazole, Pentosan, Pentoxifylline, Polysulfate sodium, Prasugrel, Rabeprazole, Rifapentine, Rivaroxaban, Salicylates, Simvastatin, Telithromycin, Thrombolytic agents, Tinzaparin, Tositumomab & Iodine131, Voriconazole, Warfarin
- See adverse reactions attributed to class:
DIMINISHED EFFECTIVENESS IN POOR METABOLIZERS
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of clopidogrel in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/27/2024
